SCHEMBL3853804

SCHEMBL3853804

CCCN(CCC)C(=O)c1cc(C(=O)O)ccc1F

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.51
MLYCD O95822 2/20 0.48
LPAR1 Q92633 2/20 0.44
LPAR5 Q9H1C0 2/20 0.44
HPGD P15428 1/20 0.43
EGFR P00533 1/20 0.42
ERBB2 P04626 1/20 0.42
RARB P10826 1/20 0.42
HCAR3 P49019 4/20 0.42
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA2 P00918 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CA9 Q16790 1/20 0.41
SLC22A6 Q4U2R8 1/20 0.41
SLC22A8 Q8TCC7 1/20 0.41
ABCC2 Q92887 1/20 0.41
SLC22A12 Q96S37 1/20 0.41
UGT1A7 Q9HAW7 1/20 0.41
SLC22A11 Q9NSA0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853802 0.88 MLYCD (0.51) TP53MLYCDLPAR1LPAR5HPGD
SCHEMBL5156702 0.81 HPGD (0.45) TP53MLYCDLPAR1LPAR5HPGD
SCHEMBL18767226 0.79 CA12 (0.53) TP53LPAR1LPAR5HPGDRAB9A
SCHEMBL26314066 0.77 MLYCD (0.64) TP53MLYCDLPAR1LPAR5HPGD
SCHEMBL1602112 0.76 RAB9A (0.46) HPGDRARBRAB9ASMN1; SMN2LMNA
SCHEMBL12491971 0.75 HPGD (0.46) MLYCDLPAR1LPAR5HPGDRARB
SCHEMBL2206424 0.74 TP53 (0.53) TP53MLYCDHPGDEGFRERBB2
SCHEMBL336060 0.74 KDM4E (0.52) TP53RAB9ACA12CA2CA9
SCHEMBL18767254 0.74 HPGD (0.51) TP53MLYCDHPGDEGFRERBB2
SCHEMBL3857013 0.74 HPGD (0.53) TP53MLYCDLPAR1LPAR5HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618978-B2 Amides as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-11-17 US disclosed
US-7585885-B2 Pyrrolidine derivatives useful as BACE inhibitors ELI LILLY AND COMPANY (US) 2009-09-08 US disclosed
US-20070225372-A1 Amides as Bace Inhibitors ELI LILLY AND COMPANY 2007-09-27 US disclosed
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS ELI LILLY AND COMPANY 2007-09-13 US disclosed
EP-1740573-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
EP-1740575-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2007-01-10 EP disclosed
WO-2005108358-A2 PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed
WO-2005108391-A1 AMIDES AS BACE INHIBITORS ELI LILLY AND COMPANY (US) 2005-11-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225372-A1 Amides as Bace Inhibitors BACE2, BACE1, APP TP53 3636/4885MLYCD 3506/4885LPAR1 2113/4885
US-20070213331-A1 PYRROLIDINE DERIVATIVES USEFUL AS BASE INHIBITORS BACE1, BACE2, PSEN1 TP53 1511/4885MLYCD 867/4885LPAR1 4547/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.